Group items tagged

Bone Marrow Transplantation (or BMT) is the specialized treatment of patients suffering from diseases like multiple sclerosis, Parkinson's disease, and multiple myeloma. Hematologic stem cells are usually taken from bone marrow. They are harvested and divided into two types namely autologous and allogenic. Autologous cells are implanted in the diseased area and they work against the disease while allogeneic cells are taken from the bone marrow and used for transplants. In general, BMT is more successful when compared to other treatment modalities. In Germany, around 13,895 people were diagnosed with leukemia with around 4% of them aged 15 years and below. One common cause of blood transfusions is the occurrence of sickle cell anemia. Sickle cell anemia is a disorder wherein the red blood cells of the body are shaped differently from normal. These blood cells are thick and might contain large amounts of iron. A bone marrow transplant can be given after the occurrence of sickle cell anemia. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2021/08/bone-marrow-transplant-has-become.html

Bone Marrow Transplant in India by the specialist doctors in best hospitals through Surgery Tours India. Contact us to Know the Cost of Bone Marrow Transplant in India.

Aplastic Anemia is a rare but serious disease of the blood cells. It is diagnosed by the inability of the bone marrow to synthesize RBCs, WBCs and platelets. The spongy bone marrow contains stem cells that are actively involved in Hematopoiesis.

Apollo Hospital offers blood and bone marrow transplant in Mumbai to treat the diseases like leukemia, aplastic anemia and many more.

Graft-versus-host disease (GvHD) is a systemic disorder and a common complication after allogeneic hematopoietic stem cell transplant. The condition can be subclassified into acute classic GVHD, persistent, recurrent, or late-onset acute GVHD, classic chronic GVHD, and overlap syndrome. High adoption of hematopoietic stem cell transplantation and increasing prevalence of certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia is expected to propel growth of the graft versus host disease (GvHD) market. For instance, according to Leukemia and Lymphoma Society, 176,200 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2019. Moreover, around 30,000 patients undergo allogeneic hematopoietic stem cell transplant annually in the United States, with approximately 20% to 85% developing aGvHD that affects the skin, gut, or liver. Increasing number of clinical trials for graft versus host disease is expected to offer lucrative growth opportunities for players in the graft versus host disease (GvHD) market. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/01/high-adoption-of-hematopoietic-stem.html

Stem cell banking is the process of collecting, processing, and storing potentially life-saving stem cells for future use. Stem cells have the potential to recreate and preserve the body, with their ability to develop into many different types of blood and tissue cell. Stem cell therapies can be used to treat diseases and repair organs and damaged tissues. Currently, cord blood stem cells can be used in transplants and therapies to treat more than 85 diseases, such as anemia, lymphomas, bone marrow cancer, and leukemia. With stem cell banking services gaining traction, adult stem cell preservation has been one of the fastest-growing areas of stem cell research. Stem cell preservation is the process of preserving stem cells that can be used for future treatments. The demand for stem cell preservation is increasing every day and is a wise investment for future medical needs. Moreover, stem cells can be used for the treatment of several life-threatening diseases, such as cancer, diabetes, and other chronic conditions. Stem cell banking offers the hope of turning these negatives into positives and helping stem cells to be effective and successful for future use. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/banking-stem-cells-is-good-idea-as-they.html

Multiple myeloma is a type of cancer that forms a type of white blood cell called a plasma cell. In multiple myeloma, cancerous plasma cells gather around the bone marrow and crowd out healthy cells. Some of the most common symptoms of multiple myeloma are pain in the back or bones, anemia, fatigue, and kidney damage. Multiple myelomas can be identified by a biopsy, which is conducted when tissue samples from the affected area are taken and examined under a microscope. When multiple myelomas are detected on an examination, it is typically very easy to remove them with a scalpel, and in many cases, surgeons will opt to remove only one lobe of tissue at a time. There has the development of various multiple myeloma drugs over the years with key industry players being involved in continuous research and development activities. Selinexor is one of the latest U.S. FDA-approved drug for multiple myeloma and is used to treat people suffering from relapsed or refractory disease. Furthermore, Ixazomib is the first and only oral proteasome inhibitor, indicated for multiple myeloma treatment. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/multiple-myeloma-drugs-are-getting.html